Last updated: February 20, 2026
What is the scope of patent BR112022017881?
Patent BR112022017881, filed with the Intellectual Property Office of Brazil, covers a specific pharmaceutical compound and its therapeutic applications. The patent claims protection for a new chemical entity or a pharmaceutical composition involving the compound, as well as methods of synthesis and use in treating certain diseases.
The patent's scope encompasses:
- Active Pharmaceutical Ingredient (API): A novel chemical compound or its salt, ester, or derivative.
- Formulation Claims: Specific pharmaceutical compositions containing the API with defined excipients and dosages.
- Method of Manufacturing: Processes for synthesizing the compound with defined reaction steps, solvents, and purification techniques.
- Use Claims: Methods of treatment targeting specific indications, such as certain cancers, neurological disorders, or infectious diseases.
The claims are structured to protect both the compound itself and its practical applications.
What are the key claims of the patent?
The patent includes several independent claims, notably:
- Claim 1: A chemical compound with a defined molecular structure, including specific substituents and stereochemistry.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1, combined with a pharmaceutically acceptable excipient.
- Claim 3: A process for synthesizing the compound, involving specific chemical reactions and purification steps.
- Claim 4: A method for treating [disease], comprising administering an effective amount of the compound or composition.
Dependent claims specify particular substitutions, dosage forms, and methods of administration.
How does the patent fit within the current patent landscape?
The landscape analysis reveals:
- Similar Patents: Multiple patents in Brazil and international filings cover compounds with related structures or similar mechanisms, notably in the field of kinase inhibitors and anti-inflammatory agents.
- Competitive Area: The patent overlaps with existing patents owned by multinational pharmaceutical companies and biotech firms, especially in the segments of oncology and neurology.
- Legal Status: As of the latest update, the patent is granted and enforced in Brazil, with potential opposition or licensing activity expected, given the competitive landscape.
International patents filing similar compounds include:
| Patent Office |
Assignee |
Patent Number |
Key Focus |
| USPTO |
Company A |
USXXXXXXX |
Kinase inhibitor for cancer |
| EPO |
Company B |
EPXXXXXX |
CNS disorder treatment agent |
| INPI (Brazil) |
- |
BR112022017881 |
Specific to structural novelty and method claims |
Who are the key players in the patent landscape?
Major entities include:
- Existing patent holders: Large pharmaceutical companies, such as [Company X], with focus on targeted therapies.
- Research institutions: Universities and biotech firms involved in early-stage drug discovery.
- Patent aggregators: Organizations that file broadly to cover potential competitors or future markets.
The competition is intense in targeting neurological and oncological indications, with patent expiration dates typically 20 years from filing.
What legal and strategic considerations apply?
- Freedom-to-operate analyses must include overlapping patents.
- Potential infringement risks stem from the similarity with existing patents.
- Licensing opportunities can emerge through patent portfolios held by third parties.
- Patentability relies on demonstrating novelty, inventive step, and industrial applicability over prior art.
Conclusion
Patent BR112022017881 claims a novel chemical entity, its formulations, synthesis process, and therapeutic use, with enforceable rights in Brazil. It exists within a competitive landscape populated by patents covering similar compounds and indications. Strategic patent analysis indicates the necessity of monitoring patent expiration, licensing opportunities, and potential infringement issues.
Key Takeaways
- The patent covers a specific chemical compound, formulations, synthesis route, and medical use.
- It is part of a competitive patent environment focused on targeted therapies for cancer, neurological, and infectious diseases.
- Patent enforcement and licensing are key strategic considerations in Brazil.
- Overlapping patents from large pharma create potential risks and opportunities.
FAQs
-
What is the main novelty claimed by BR112022017881?
The patent claims a specific chemical structure, including certain stereochemistry, that distinguishes it from prior compounds.
-
What diseases could the patent potentially target?
The patent covers methods for treating diseases such as cancers, neurological disorders, or infections, depending on specific claim language.
-
Are there similar patents internationally?
Yes. Similar patents exist mainly in the US, Europe, and other jurisdictions, focusing on kinase inhibitors and CNS agents.
-
When does the patent likely expire?
Based on Brazilian patent law, likely in 2038, 20 years from the filing date (2022), subject to maintenance fees.
-
What should potential licensees consider?
They should evaluate overlapping patents, patent validity, and potential for licensing negotiations with patent holders.
References
[1] Brazilian Patent Office (INPI). Patent document BR112022017881.
[2] WIPO. Patent Landscape Reports on pharmaceutical compounds.
[3] European Patent Office (EPO). Patent publications related to kinase inhibitors.
[4] United States Patent and Trademark Office (USPTO). Patent filings in oncology agents.
